Skip to main content
Erschienen in: Clinical and Experimental Nephrology 1/2013

01.02.2013 | Letter to the Editor

Febuxostat for hyperuricemia: experience with patients on chronic hemodialysis treatment

verfasst von: Ryoko Horikoshi, Tetsu Akimoto, Makoto Inoue, Yoshiyuki Morishita, Eiji Kusano

Erschienen in: Clinical and Experimental Nephrology | Ausgabe 1/2013

Einloggen, um Zugang zu erhalten

Excerpt

To the Editor
Literatur
1.
Zurück zum Zitat Hosoya T, Ono I. A repeated oral administration study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with impaired renal function in Japan: pharmacokinetic and pharmacodynamic study. J Clin Rheumatol. 2011;17(4 suppl 2):S27–34. Hosoya T, Ono I. A repeated oral administration study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with impaired renal function in Japan: pharmacokinetic and pharmacodynamic study. J Clin Rheumatol. 2011;17(4 suppl 2):S27–34.
2.
Zurück zum Zitat Yamanaka H; Japanese Society of Gout and Nucleic Acid Metabolism. Japanese guideline for the management of hyperuricemia and gout: second edition. Nucleosides Nucleotides Nucleic Acids. 2011;30:1018–29.CrossRef Yamanaka H; Japanese Society of Gout and Nucleic Acid Metabolism. Japanese guideline for the management of hyperuricemia and gout: second edition. Nucleosides Nucleotides Nucleic Acids. 2011;30:1018–29.CrossRef
3.
Zurück zum Zitat El-Zawawy H, Mandell BF. Managing gout: how is it different in patients with chronic kidney disease? Cleve Clin J Med. 2010;77:919–28.PubMedCrossRef El-Zawawy H, Mandell BF. Managing gout: how is it different in patients with chronic kidney disease? Cleve Clin J Med. 2010;77:919–28.PubMedCrossRef
4.
Zurück zum Zitat Latif W, Karaboyas A, Tong L, Winchester JF, Arrington CJ, Pisoni RL, Marshall MR, Kleophas W, Levin NW, Sen A, Robinson BM, Saran R. Uric acid levels and all-cause and cardiovascular mortality in the hemodialysis population. Clin J Am Soc Nephrol. 2011;6:2470–7.PubMedCrossRef Latif W, Karaboyas A, Tong L, Winchester JF, Arrington CJ, Pisoni RL, Marshall MR, Kleophas W, Levin NW, Sen A, Robinson BM, Saran R. Uric acid levels and all-cause and cardiovascular mortality in the hemodialysis population. Clin J Am Soc Nephrol. 2011;6:2470–7.PubMedCrossRef
5.
Zurück zum Zitat Tsuda H, Kawada N, Kaimori JY, Kitamura H, Moriyama T, Rakugi H, Takahara S, Isaka Y. Febuxostat suppressed renal ischemia-reperfusion injury via reduced oxidative stress. Biochem Biophys Res Commun. 2012;427:266–72.PubMedCrossRef Tsuda H, Kawada N, Kaimori JY, Kitamura H, Moriyama T, Rakugi H, Takahara S, Isaka Y. Febuxostat suppressed renal ischemia-reperfusion injury via reduced oxidative stress. Biochem Biophys Res Commun. 2012;427:266–72.PubMedCrossRef
Metadaten
Titel
Febuxostat for hyperuricemia: experience with patients on chronic hemodialysis treatment
verfasst von
Ryoko Horikoshi
Tetsu Akimoto
Makoto Inoue
Yoshiyuki Morishita
Eiji Kusano
Publikationsdatum
01.02.2013
Verlag
Springer Japan
Erschienen in
Clinical and Experimental Nephrology / Ausgabe 1/2013
Print ISSN: 1342-1751
Elektronische ISSN: 1437-7799
DOI
https://doi.org/10.1007/s10157-012-0763-7

Weitere Artikel der Ausgabe 1/2013

Clinical and Experimental Nephrology 1/2013 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.